These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 26998170)

  • 1. Prognostic analysis of triple-negative breast cancer patients treated with adjuvant chemotherapy of fluorouracil, epirubicin and cyclophosphamide.
    Sun W; Li C; Liu M; Liu W; Yang C; Cai LI
    Oncol Lett; 2016 Mar; 11(3):2320-2326. PubMed ID: 26998170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of type 2 diabetes mellitus on the prognosis of early stage triple-negative breast cancer in People's Republic of China.
    Ma FJ; Liu ZB; Qu L; Hao S; Liu GY; Wu J; Shao ZM
    Onco Targets Ther; 2014; 7():2147-54. PubMed ID: 25473296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer.
    Campone M; Lacroix-Triki M; Roca L; Spielmann M; Wildiers H; Cottu P; Kerbrat P; Levy C; Desmoulins I; Bachelot T; Winston T; Eymard JC; Uwer L; Duhoux FP; Verhoeven D; Jaubert D; Coeffic D; Orfeuvre H; Canon JL; Asselain B; Martin AL; Lemonnier J; Roché H
    Eur J Cancer; 2018 Nov; 103():184-194. PubMed ID: 30267987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the outcomes of non-randomised chemotherapy regimens in node positive breast cancer.
    Kuru B; Camlibel M; Dinc S; Gulcelik MA; Atalay C; Alagol H
    J Exp Clin Cancer Res; 2005 Sep; 24(3):363-72. PubMed ID: 16270522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized clinical trial of adjuvant fluorouracil, epirubicin, and cyclophosphamide chemotherapy for patients with fast-proliferating, node-negative breast cancer.
    Paradiso A; Schittulli F; Cellamare G; Mangia A; Marzullo F; Lorusso V; De Lena M
    J Clin Oncol; 2001 Oct; 19(19):3929-37. PubMed ID: 11579113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
    Mavroudis D; Matikas A; Malamos N; Papakotoulas P; Kakolyris S; Boukovinas I; Athanasiadis A; Kentepozidis N; Ziras N; Katsaounis P; Saloustros E; Georgoulias V;
    Ann Oncol; 2016 Oct; 27(10):1873-8. PubMed ID: 27502729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer.
    Lim ST; Park CH; Kim SY; Nam SJ; Kang EY; Moon BI; Lee HJ; Jeon YW; Gwak H; Suh YJ
    PLoS One; 2018; 13(5):e0197523. PubMed ID: 29768496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106).
    Kerbrat P; Desmoulins I; Roca L; Levy C; Lortholary A; Marre A; Delva R; Rios M; Viens P; Brain É; Serin D; Edel M; Debled M; Campone M; Mourret-Reynier MA; Bachelot T; Foucher-Goudier MJ; Asselain B; Lemonnier J; Martin AL; Roché H
    Eur J Cancer; 2017 Jul; 79():166-175. PubMed ID: 28501763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of locoregional and systemic treatment in operable high-risk breast cancer patients with more than four positive axillary lymph nodes.
    Yin K; Zhou L; Shao Z; Yin W; Lu J
    Onco Targets Ther; 2015; 8():2665-73. PubMed ID: 26442757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).
    Polyzos A; Malamos N; Boukovinas I; Adamou A; Ziras N; Kalbakis K; Kakolyris S; Syrigos K; Papakotoulas P; Kouroussis C; Karvounis N; Vamvakas L; Christophyllakis C; Athanasiadis A; Varthalitis I; Georgoulias V; Mavroudis D
    Breast Cancer Res Treat; 2010 Jan; 119(1):95-104. PubMed ID: 19636702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.
    Fumoleau P; Kerbrat P; Romestaing P; Fargeot P; Brémond A; Namer M; Schraub S; Goudier MJ; Mihura J; Monnier A; Clavère P; Serin D; Seffert P; Pourny C; Facchini T; Jacquin JP; Sztermer JF; Datchary J; Ramos R; Luporsi E
    J Clin Oncol; 2003 Jan; 21(2):298-305. PubMed ID: 12525522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Outcome of Patients with Triple Negative Breast Cancer: The Turkish Oncology Group Experience.
    Eralp Y; Kılıç L; Alço G; Başaran G; Doğan M; Dinçol D; Demirci S; İçli F; Onur H; Saip P; Haydaroğlu A
    J Breast Health; 2014 Oct; 10(4):209-215. PubMed ID: 28331673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial.
    French Adjuvant Study Group
    J Clin Oncol; 2001 Feb; 19(3):602-11. PubMed ID: 11157009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Cumulative Chemotherapy Dose on Survival With Adjuvant FEC-D Chemotherapy for Breast Cancer.
    Veitch Z; Khan OF; Tilley D; Tang PA; Ribnikar D; Stewart DA; Kostaras X; King K; Lupichuk S
    J Natl Compr Canc Netw; 2019 Aug; 17(8):957-967. PubMed ID: 31390594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymph node ratio as best prognostic factor in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy.
    De la Cruz-Ku GA; Chambergo-Michilot D; Valcarcel B; Rebaza P; Möller M; Araujo JM; Enriquez D; Morante Z; Razuri C; Luque R; Saavedra A; Eyzaguirre E; Lujan M; Noel N; Pinto J; Cotrina J; Gomez H
    Breast J; 2020 Sep; 26(9):1659-1666. PubMed ID: 32713113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological and Prognostic Characteristics of Malaysian Triple Negative Breast Cancer Patients Undergoing TAC Chemotherapy Regimen.
    Abdul Aziz AA; Md Salleh MS; Ankathil R
    Int J Breast Cancer; 2020; 2020():8424365. PubMed ID: 32308997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101.
    Narui K; Ishikawa T; Shimizu D; Yamada A; Tanabe M; Sasaki T; Oba MS; Morita S; Nawata S; Kida K; Mogaki M; Doi T; Tsugawa K; Ogata H; Ota T; Kosaka Y; Sengoku N; Kuranami M; Niikura N; Saito Y; Suzuki Y; Suto A; Arioka H; Chishima T; Ichikawa Y; Endo I; Tokuda Y
    Breast; 2019 Oct; 47():1-9. PubMed ID: 31229857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of patients with node-negative, triple-negative breast cancer who benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy.
    Wu CE; Chen SC; Lin YC; Lo YF; Hsueh S; Chang HK
    Anticancer Res; 2014 Mar; 34(3):1301-6. PubMed ID: 24596377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial.
    Del Mastro L; Levaggi A; Michelotti A; Cavazzini G; Adami F; Scotto T; Piras M; Danese S; Garrone O; Durando A; Accortanzo V; Bighin C; Miglietta L; Pastorino S; Pronzato P; Castiglione F; Landucci E; Conte P; Bruzzi P
    Breast Cancer Res Treat; 2016 Jan; 155(1):117-26. PubMed ID: 26661403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.